Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity (Q33392920)
scientific article published on November 18, 2010
Language:
(P31) (Q13442814)
(P50) (Q104437536)
(Q110350523)
(Q89672650)
(Q114521842)
(P304) 1149-1159
(P407) (Q1860)
(P433) 12
(P478) 11
(P577) Thursday, November 18, 2010
(P921) (Q323936)
(Q725307)
(P953) https://europepmc.org/articles/pmc3025495?pdf=render
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21094089/pdf/?tool=EBI
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21094089/?tool=EBI
https://europepmc.org/articles/PMC3025495
https://europepmc.org/articles/PMC3025495?pdf=render
https://doi.org/10.1016/s1470-2045(10)70261-8
https://api.elsevier.com/content/article/PII:S1470204510702618?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S1470204510702618?httpAccept=text/plain
(P1433) (Q13747613)
(P1476) "Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity" (language: en)
(P2093) Anil Tulpule
Hao Xiong
Yi-Lin Chiu
Yue Cui
Todd Busman
Myron S. Czuczman
John F. Gerecitano
John P. Leonard
Steven W. Elmore
Saul H. Rosenberg
Andrew P. Krivoshik
Sari H. Enschede
Rod A. Humerickhouse
(P2860) (Q33392029)
(Q36988067)
(Q24613755)
(Q28247489)
(Q34066960)
(Q37068553)
(Q39924324)
(Q33381678)
(Q29616727)
(Q24616084)
(Q36288687)
(Q24337209)
(Q33374664)
(Q35250940)
(Q28279141)
(Q29547595)
(Q36009696)
(Q35102934)
(Q28240722)
(Q42608652)
(Q28200040)
(Q33332247)
(Q33773306)
(Q27851513)
(Q36362035)
(Q28510299)
(Q34245495)
(Q48375088)
(Q41964290)
(Q29620000)
(Q36508777)
(Q43763736)
(Q46247309)
(Q53581386)
(Q56609201)
(Q74257381)
(Q62817743)
(Q67903593)
(Q61053586)
(Q73937593)
(Q79641911)
(Q25938997)
other details
description scientific article published on November 18, 2010

External Links